Lisa M Chirch1, Sidonie Morrison, Roy T Steigbigel. 1. Division of Infectious Diseases, Stony Brook University School of Medicine, Health Sciences Center T15-080, Stony Brook, NY 11794-8153, USA. lisa.chirch@stonybrook.edu
Abstract
BACKGROUND: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus. OBJECTIVE: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability. METHODS: Data from pharmacokinetic, Phase II and III clinical trials were reviewed. RESULTS/ CONCLUSIONS: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
BACKGROUND:Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus. OBJECTIVE: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability. METHODS: Data from pharmacokinetic, Phase II and III clinical trials were reviewed. RESULTS/ CONCLUSIONS: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
Authors: Stefania Ferro; Sara De Grazia; Laura De Luca; Rosaria Gitto; Caterina Elisa Faliti; Zeger Debyzer; Alba Chimirri Journal: Molecules Date: 2011-08-11 Impact factor: 4.411
Authors: Said A Hassounah; Thibault Mesplède; Peter K Quashie; Maureen Oliveira; Paul A Sandstrom; Mark A Wainberg Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino Journal: Retrovirology Date: 2010-03-16 Impact factor: 4.602
Authors: Darren M Moss; Wai San Kwan; Neill J Liptrott; Darren L Smith; Marco Siccardi; Saye H Khoo; David J Back; Andrew Owen Journal: Antimicrob Agents Chemother Date: 2010-11-15 Impact factor: 5.191